Carl Howard June - 11 Jun 2026 Form 4 Insider Report for AC Immune SA (ACIU)

Reporting relationship: Director
Issuer ticker: ACIU
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 06:31:33 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: Matthias Maurer as Attorney-in-Fact for Carl June

Key filing fact

Carl Howard June filed Form 4 for AC Immune SA (ACIU) on 15 Jun 2026.

Key facts

This page summarizes Carl Howard June's Form 4 filing for AC Immune SA (ACIU).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 06:31.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002116422 Primary reporting owner

June Carl Howard

Relationship: Director
Address: 409 BAIRD RD, MERION
Signature: Matthias Maurer as Attorney-in-Fact for Carl June
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACIU transaction

Common Share

Award

Transaction value
Shares: +16,568
Change %: +32%
Price: $0.000000^*
Shares after: 67,556
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACIU transaction Derivative

Share Option (right to buy)

Award

Transaction value
Shares: +38,889
Change %
Price: $0.000000^*
Shares after: 38,889
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Share
Underlying amount: 38,889
Exercise price: $2.62
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP).

Footnote F2

Includes 66,556 common shares underlying outstanding restricted share units.

Footnote F3

On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027.